Fluoguide AS
STO:FLUO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.9
75.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
PP&E Net
Fluoguide AS
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
PP&E Net
kr824k
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
PP&E Net
kr1.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
39%
|
CAGR 10-Years
55%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
PP&E Net
kr128.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
21%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
PP&E Net
€97.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
48%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
PP&E Net
kr2.4B
|
CAGR 3-Years
24%
|
CAGR 5-Years
25%
|
CAGR 10-Years
22%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
PP&E Net
kr1.1m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
4%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's PP&E Net?
PP&E Net
824k
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's PP&E Net amounts to 824k DKK.
What is Fluoguide AS's PP&E Net growth rate?
PP&E Net CAGR 3Y
57%
Over the last year, the PP&E Net growth was 240%. The average annual PP&E Net growth rates for Fluoguide AS have been 57% over the past three years .
You don't have any saved screeners yet
